1. Home
  2. BGLC vs BIVI Comparison

BGLC vs BIVI Comparison

Compare BGLC & BIVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo BioNexus Gene Lab Corp

BGLC

BioNexus Gene Lab Corp

N/A

Current Price

$3.05

Market Cap

10.1M

Sector

Health Care

ML Signal

N/A

Logo BioVie Inc.

BIVI

BioVie Inc.

HOLD

Current Price

$1.23

Market Cap

9.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BGLC
BIVI
Founded
2017
2013
Country
Malaysia
United States
Employees
N/A
N/A
Industry
Medical Specialities
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
10.1M
9.2M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
BGLC
BIVI
Price
$3.05
$1.23
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
8.0K
131.5K
Earning Date
11-14-2025
02-09-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$9,465,006.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
2.21
N/A
52 Week Low
$2.01
$1.10
52 Week High
$15.60
$20.40

Technical Indicators

Market Signals
Indicator
BGLC
BIVI
Relative Strength Index (RSI) 23.39 43.19
Support Level $3.02 $1.17
Resistance Level $3.52 $1.30
Average True Range (ATR) 0.22 0.07
MACD -0.06 0.01
Stochastic Oscillator 0.00 28.07

Price Performance

Historical Comparison
BGLC
BIVI

About BGLC BioNexus Gene Lab Corp

BioNexus Gene Lab Corp, through its wholly owned subsidiary, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries in the Southeast Asia region. These countries include Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. In addition, the Company is in the business of developing and providing safe, effective, and non-invasive liquid biopsy tests for the early detection of biomarkers that it believes are linked to diseases to minimize treatment costs and improve patient management. Its non-invasive blood tests provide analysis of changes in RNA to detect the potential risk of different diseases.

About BIVI BioVie Inc.

BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.

Share on Social Networks: